A 63-year-old woman developed severe low blood sugar episodes after starting tirzepatide for weight loss, which led to the discovery of a previously undiagnosed insulinoma — highlighting an important diagnostic consideration as incretin-based drugs become widely used.
Insulinoma unmasked by tirzepatideSevere postprandial hypoglycemia in a non-diabetic patient on tirzepatide for weight loss led to diagnosis of a previously hidden insulin-producing tumor
What the researchers found
Tirzepatide use in a 63-year-old non-diabetic woman provoked severe postprandial hypoglycemia that led to the diagnosis of insulinoma. The incretin-based mechanism of tirzepatide (stimulating glucose-dependent insulin secretion via GLP-1 and GIP receptors) exacerbated the already excessive insulin production from the tumor, causing dangerously low blood sugar levels.
This case establishes that tirzepatide can unmask or worsen insulinoma-related hypoglycemia and highlights the need to include insulinoma in the differential diagnosis when patients on incretin-based therapies develop unexpected hypoglycemic episodes.
Why it matters
As millions of people start taking GLP-1/GIP receptor agonists for weight loss, rare but important drug-disease interactions will increasingly surface. Insulinomas affect about 1-4 per million people annually, but many go undiagnosed for years. With tirzepatide now being prescribed to a huge non-diabetic population, clinicians need to recognize that severe hypoglycemia in these patients may signal an underlying insulinoma rather than just a drug side effect. Early diagnosis of insulinoma is critical because it's typically curable with surgery.
How the study worked
Single patient case report documenting the clinical presentation, diagnostic workup, and outcomes of a 63-year-old non-diabetic woman who developed severe postprandial hypoglycemia after starting tirzepatide for weight management.
What this study cannot tell us
Single case report — cannot establish the frequency of this interaction or predict which patients are at risk. The rarity of insulinoma means prospective studies would be extremely difficult. It's possible that the patient would have eventually been diagnosed without tirzepatide, though the drug clearly accelerated the presentation. The specific tirzepatide dose and timeline are not detailed in the abstract.
How to read the evidence
Single case report providing the lowest level of clinical evidence. However, for rare adverse events and drug-disease interactions, case reports are often the first and most important signal. This case establishes a plausible mechanistic link between tirzepatide's insulin-stimulating effects and insulinoma exacerbation.
When this study was published
Published in 2026, this is a very recent case report reflecting the expanding use of tirzepatide in non-diabetic populations for weight management — a clinical context that barely existed a few years ago.
The bigger picture
This case represents an emerging category of medical knowledge: unexpected consequences of widespread GLP-1/GIP agonist use in previously untreated populations. As these drugs move from diabetic to non-diabetic patients for weight management, new drug-disease interactions will surface. Insulinoma is one example, but clinicians should be broadly alert to the possibility that incretin-based drugs could unmask or worsen other conditions involving insulin signaling or glucose regulation.
Questions still open
- Should patients be screened for insulinoma before starting incretin-based therapy, or is the condition too rare to justify screening?
- How many other undiagnosed insulinomas might be unmasked as GLP-1/GIP agonist use expands to millions of non-diabetic patients?
- Are there other rare conditions that GLP-1/GIP agonists could similarly unmask in the weight management population?
Common questions
What is an insulinoma and why is it important?
Why would tirzepatide make an insulinoma worse?
Read the original research
Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.
JCEM case reports, 4(1), luaf290
Citation
Polisky, Michael; Kamel, Dina; Ku, Jeong-Hee. (2026). Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.. JCEM case reports, 4(1), luaf290. https://doi.org/10.1210/jcemcr/luaf290